Stay updated with breaking news from Nicole Bean. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A pair of biotechs burst onto the scene Tuesday, exiting stealth with $100 million in financing each and tapping executives who made their names at bluebird bio and Karuna Therapeutics.
The approvals, third line for BMS and 2seventy Bio’s Abecma and second line for J&J and Legend Biotech’s Carvykti, represent a new class of therapy for these blood cancer patients.
A controversial decision by the Alabama Supreme Court temporarily chilled IVF before igniting nationwide pushes to protect access to this type of fertility treatment, leaving drugmakers with questions.
With the potential FDA approval of an MDMA-based therapy for PTSD on the horizon, biopharma stakeholders are eyeing psychedelics with fresh anticipation.
Pictured: Money floats by skyscrapers, including one from which a white flag waves/Nicole Bean for BioSpace Bankruptcy among biotechs is on the rise, with a…